Pancreatic ductal adenocarcinoma (PDAC) is notoriously hard to treat. In a study published by Nature Genetics, Jacks and Regev Lab researchers used single-cell analysis tools to categorize how different subpopulations of cells respond to therapeutic interventions. Their findings reveal new vulnerabilities in the PDAC landscape and opportunities for more personalized treatment in the clinic.